Vaccinia Virus Vector Bivalent Norovirus Vaccine

Area of Science:

• Virology
• Vaccinology
• Immunology

Background:

• Norovirus is a leading cause of gastroenteritis globally.
• Current challenges include norovirus diversity and lack of broad-spectrum vaccines.
• An urgent need exists for effective, polyvalent norovirus vaccines.

Purpose of the Study:

• To develop and evaluate a bivalent norovirus vaccine candidate.
• To assess the immunogenicity and safety of a novel poxvirus vector vaccine.
• To explore broad-spectrum protection against diverse norovirus genotypes.

Main Methods:

• Construction of a bivalent vaccine using an attenuated poxvirus (VG9) vector.
• Expression of norovirus major capsid protein VP1 from GII.4 and GII.17 genotypes.
• Immunization of mice via intramuscular and intranasal routes.
• Assessment of antibody titers, neutralizing antibody activity, and cellular immune responses.

Main Results:

• The VG9-NOR vaccine demonstrated safe replication comparable to the wild-type virus.
• High IgG and IgA antibody titers against GII.4 and GII.17 were induced.
• Increased secretion of blocking antibodies and enhanced mucosal immunity were observed.
• A Th1-mediated cellular immune response was elicited.

Conclusions:

• The polyvalent poxvirus vector vaccine effectively elicits protection against multiple norovirus subtypes.
• The VG9 vector is a promising platform for developing broad-spectrum norovirus vaccines.
• This approach offers a potential solution to the unmet need for global norovirus vaccination.